Extraction, Gene Regulation and Hypocholesterolemic Effects, and Antioxidative Activity of Thymoquinone Rich Fraction and Thymoquinone from Nigella Sativa (pdf incomplete) by Al-Naqeeb, Ghanya Naji
  
UNIVERSITI PUTRA MALAYSIA 
 
EXTRACTION, GENE REGULATION AND 
HYPOCHOLESTEROLEMIC EFFECTS, AND ANTIOXIDATIVE 
ACTIVITY OF THYMOQUINONE RICH FRACTION AND 
THYMOQUINONE FROM NIGELLA SATIVA 
 
 
 
 
 
 
 
 
 
 
 
GHANYA NAJI AL-NAQEEB 
 
FPSK(P) 2009 5 
 
 
EXTRACTION, GENE REGULATION AND HYPOCHOLESTEROLEMIC 
EFFECTS, AND ANTIOXIDATIVE ACTIVITY OF THYMOQUINONE 
RICH FRACTION AND THYMOQUINONE FROM NIGELLA SATIVA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
By 
 
GHANYA NAJI AL-NAQEEB 
 
 
 
 
 
 
 
 
 
Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, 
in Fulfilment of the Requirements for the Degree of Doctor of Philosophy 
 
 
August 2009 
 
Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment 
of the requirement for the degree of Doctor of Philosophy 
 
EXTRACTION, GENE REGULATION AND HYPOCHOLESTEROLEMIC 
EFFECTS, AND ANTIOXIDATIVE ACTIVITY OF THYMOQUINONE 
RICH FRACTION AND THYMOQUINONE FROM NIGELLA SATIVA 
 
By 
GHANYA NAJI AL-NAQEEB 
August 2009 
Chairman:       Professor. Maznah Ismail, PhD 
Faculty     :       Medicine and Health Sciences 
 
 
Nigella sativa and its active constituent thymoquinone (TQ) have been used for 
various health benefits such as antitumor, antidiabetic, antihypertensive, 
antioxidatative and antibacterial. The present study involves thymoquinone rich 
fraction (TQRF) prepared from Nigella sativa seeds using supercritical fluid 
extraction (SFE) and commercial available thymoquinone (TQ) to investigate their 
regulatory effects on genes involved in cholesterol metabolism in vitro using 
Human liver cancer cells (HepG2 cells) and in vivo using Sprague-Dawley rats. In 
the present study, SFE extraction procedures with different parameters of pressure 
at 400 and 600 bar and temperature at 40, 60 and 80°C were optimized to prepare 
TQRF. The yield of the oil content was highest (37%) at a high temperature of 80°C 
and a high pressure of 600 bars. The TQ content in different fractions of oil was the 
highest (2%) at a low temperature of 40°C and a high pressure of 600 bars 
compared to other used parameters. The major fatty acids in TQRF were oleic and 
linolenic which exist as unsaturated fatty acids. Palmitic, stearic and myristic acids 
were the main saturated fatty acids. TQRF was rich in α-tocopherol content (290 ± 
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1.5 mg/100g). HepG2 cells viability was determined using MTT assay and flow 
cytrometry. TQRF and TQ were shown to inhibit HepG2 cells growth with IC50 of 
100 µg/ml for TQRF and 3.5 µg/ml for TQ after 72 h incubation. Flow cytometry 
analysis showed that the cells viability was more than 80% when HepG2 cells were 
treated with TQRF at 50 μg/ml and TQ at 2 μg/ml. The regulatory effects of TQRF 
at 50 and 80 µg/ml and TQ at 2 μg/ml on genes involved in cholesterol metabolism 
were studied in HepG2 cell using real time polymerase chain reaction. These genes 
included low density lipoprotein receptor (LDLR), 3-hydroxy-3-methylglutaryl-
coenzyme A reductase (HMG-COAR), apolipoproteins (Apo) including Apo A-1 
and Apo B100. When cells were treated with TQRF at 50 and 80 µg/ml and TQ at 2 
µg/ml mRNA level of LDLR gene was up-regulated by 3, 7 and 2 fold respectively, 
compared to untreated cells. On the other hand, mRNA level of HMG-COAR was 
down-regulated by 37, 71 and 12% respectively, compared to untreated cells. The 
mRNA level of Apo A-1 gene was up-regulated by 3, 4 and 2 fold and Apo B100 
was suppressed by 60, 70 and 49% respectively, when cells were treated with TQRF 
at 50 and 80 µg/ml and TQ at 2 µg/ml compared to untreated cells.  TQRF at dose 
of 0.5, 1 and 1.5 g/kg and TQ at 20, 50 and 100 mg/kg body weight in emulsion 
form were administrated orally to the rats fed diet supplemented with 1% 
cholesterol for 8 weeks. There was a significant reduction in plasma total 
cholesterol levels (TC) and low density lipoprotein cholesterol (LDLC) in both 
TQRF and TQ at different doses compared to cholesterol control rats (PC). The 
concentration of the alanine aminotransferase (ALT), gamma 
glutamyltranspeptidase (GGT), urea and creatinine of plasma collected from 
experimental rats were also measured in this experiment to test any toxic effect of 
TQRF and TQ on liver and kidney of rats. ALT, GGT and urea levels were 
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significantly lower in TQRF and TQ treated groups compared to PC group. The 
antioxidant activity of TQRF and TQ treatment as hydroxyl radical (OH·) 
scavenging activity in plasma samples collected from experimental rats was also 
carried out using electron spin resonance (ESR). The findings showed significantly 
higher of OH· scavenging activity in TQRF and TQ treated rats at different doses 
compared to untreated rats. The regulatory effect of TQRF and TQ treatment on 
hepatic genes involved in cholesterol metabolism including LDLR, HMG-COAR, 
Apo A-1, Apo B100 and Apo E genes were also investigated in vivo. Treating rats 
with TQRF at dose of 0.5, 1 and 1.5 g/kg and TQ at 20, 50 and 100 mg/kg body 
weight showed up-regulation of LDLR and Apo E genes whereas both treatments in 
the same doses showed down-regulation of HMG-COAR and Apo B100 genes 
compared to untreated rats. In conclusion, the present study suggests that TQRF and 
TQ generated a hypocholesterolemic effect through regulation of key genes 
involved in cholesterol metabolism. Both in vitro and in vivo results demonstrate 
potential value of TQRF and TQ as a novel cholesterol lowering and antioxidant 
candidate. 
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Nigella sativa dan sebatian aktifnya, timokuinon (TQ) telah digunakan secara 
meluas dalam bidang perubatan dan kesihatan sebagai agen antitumor, antidiabetik, 
antihipertensi, antioksidatif dan anti-bakteria. Kajian ini bertujuan untuk mengkaji 
kesan rawatan fraksi kaya timokuinon (TQRF) (disediakan dari biji benih Nigella 
sativa dengan menggunakan kaedah pengekstrakan bendalir superkritikal, SFE) dan 
timokuinon (TQ) komersial terhadap pengawalaturan gen yang terlibat dalam 
metabolisma kolesterol, dengan menggunakan sel kanser hati manusia (sel HepG2) 
secara in vitro dan tikus Sprague-Dawley secara in vivo. Dalam kajian ini, tekanan 
pengekstrakan SFE yang berjulat dari 400 hingga 600 bars bersama-sama dengan  
suhu pengekstrakan pada 40, 60 dan  80°C telah dioptimakan untuk menyediakan 
TQRF. Kebolehdapatan minyak yang tertinggi (37%) didapati apabila 
pengekstrakan SFE dijalankan pada  suhu 80°C bersama-sama dengan tekanan 
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tinggi iaitu pada 600 bars. Kandungan TQ yang tertinggi (2%) pula didapati pada 
minyak SFE yang diekstrak pada suhu rendah iaitu 40°C bersama-sama dengan 
tekanan pengekstrakan 600 bars. Kandungan asid lemak utama dalam TQRF adalah 
oleik dan linoleik yang hadir sebagai asid lemak tak tepu. Manakala asid palmitik, 
stearik dan miristik pula merupakan asid lemak tepu yang utama dalam TQRF. 
Fraksi kaya timokuinon didapati kaya dengan α tokoferol (290 ± 1.5 mg/100g). 
Pertumbuhan sel HepG2 telah dikaji dengan menggunakan kaedah asai MTT dan 
sitometri pengaliran. TQRF dan TQ telah menunjukkan kesan perencatan terhadap 
pertumbuhan sel HepG2 dengan bacaan IC50 masing-masing pada 100 µg/ml dan 
3.5 µg/ml selepas pengeraman selama 72 jam. Analisis dari sitometri pengaliran 
menunjukkan bahawa pertumbuhan sel HepG2 adalah melebihi 80% apabila sel 
tersebut dirawati dengan TQRF pada 50 μg/ml dan TQ pada 2 μg/ml.  Kesan 
rawatan TQRF (pada 50 dan 80 µg/ml) dan TQ (pada 2 μg/ml) terhadap 
pengawalaturan gen yang terlibat dalam metabolisma kolesterol dalam sel HepG2 
telah dikaji dengan menggunakan kaedah tindakbalas berantai polimerase masa 
nyata. Gen – gen yang terlibat adalah termasuk reseptor lipoprotein berketumpatan 
rendah (LDLR), reduktase 3-hidroksi-3-metilglutaril-koenzim A (HMG-CoAR), 
apolipoprotein (Apo) iaitu Apo A-1, Apo B100 dan Apo E. Keputusan 
menunjukkan bahawa sel yang dirawati dengan TQRF pada 50 dan 80 µg/ml dan 
TQ pada 2 µg/ml masing-masing menunjukkan peningkatan pengawalaturan gen 
LDLR dengan peningkatan tahap mRNAnya sebanyak 3, 7 dan 2 kali ganda  
berbanding dengan sel yang tidak dirawati. Sebaliknya, pengawalaturan gen HMG-
COAR masing-masing direncatkan sebanyak 37, 71 dan 12%, berbanding dengan 
sel yang tidak dirawati. Selain daripada itu, rawatan TQRF (50 dan 80 µg/ml) dan 
TQ (2µg/ml) juga didapati meningkatkan pengawalaturan gen Apo A-1 (sebanyak 
 vi
3, 4 dan 2 kali ganda masing-masing) dan merencatkan pengawalaturan gen Apo 
B100 (sebanyak 60, 70 dan 49% masing-masing). TQRF pada dos 0.5, 1 dan 1.5 
g/kg dan TQ pada 20, 50 dan 100 mg/kg berat badan dalam bentuk emulsi telah 
diberikan secara oral kepada tikus yang  telah diberi makanan yang mengandungi 
1% kolesterol tambahan selama 8 minggu. Rawatan TQRF dan TQ pada kepekatan 
yang berbeza-beza didapati menurunkan tahap kolesterol jumlah plasma (TC) dan 
kolesterol lipoprotein berketumpatan  rendah (LDLC) dalam tikus secara signifikan 
jika dibanding dengan tahap kolesterol tikus kawalan (PC). Kepekatan alanina 
aminotransferase (ALT), gama glutamiltranspeptidase (GGT), uria dan  kreatinin 
dalam plasma tikus telah diukur dalam ujikaji ini bagi mengenalpasti ketoksikan 
TQRF dan TQ terhadap hati dan buah pinggang tikus. Keputusan menunjukkan 
bahawa tahap ALT, GGT dan uria dalam plasma tikus yang dirawati oleh TQRF 
dan TQ adalah lebih rendah daripada plasma tikus dari kumpulan PC. Aktiviti 
antioksida plasma tikus telah dinilai melalui ujian pemerangkapan radikal hiroksil 
(OH·) yang diukur dengan spektrometer resonan pemusingan elektron (ESR). 
Keputusan ESR menunjukkan bahawa rawatan TQRF dan TQ pada kepekatan yang 
berbeza-beza didapati meningkatkan aktiviti pemerangkapan radikal hidroksil 
dalam plasma tikus secara signifikan jika dibanding dengan tikus kawalan. Kesan 
rawatan TQRF dan TQ terhadap pengawalaturan gen-gen yang terlibat dalam 
metabolisma kolesterol ( LDLR, HMG-COAR, gen Apo A-1, Apo B100 dan Apo 
E) turut dikaji dalam model in vivo. Keputusan menunjukkan bahawa rawatan 
TQRF pada kadar dos 0.5, 1 dan 1.5 g/kg dan TQ pada kadar 20, 50 dan 100 mg/kg 
berat badan menunjukkan peningkatan pengawalaturan dalam gen LDLR dan gen 
Apo E tetapi menunjukkan kesan perencatan terhadap pengawalaturan gen HMG – 
CoAR dan gen Apo B100 dalam model tikus. Kesimpulannya, kajian ini 
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mencadangkan bahawa TQRF dan TQ menunjukkan kesan hipokolesterolemik 
melalui proses pengawalaturan gen – gen penting yang terlibat dalam metabolisma 
kolesterol. Hasil dari ujikaji secara in vitro dan in vivo mengesyorkan bahawa 
TQRF dan TQ mempunyai potensi yang tinggi sebagai agen penurunan paras 
kolesterol dalam badan dan sebagai antipengoksida. 
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CHAPTER 1 
 
INTRODUCTION 
 
Cardiovascular diseases (CVD) are considered to be the frequent cause of most 
deaths in the world, and the current trend is expected to persist till the year 2020 
with over 25 million deaths annually (Murray and Lopez, 1997). An estimated 17.5 
million people died from cardiovascular disease in 2005, representing 30 % of all 
global deaths. Of these deaths, 7.6 million were due to coronary heart disease (CHD) 
(WHO, 2005). In the United States, 300,000 individuals each year suffer sudden CVD 
(Rosamond et al., 2007) 80% of which are of atherosclerotic origin (Wang 2005). CVD 
was accounted for between 23% to 26% of deaths in Malaysian government 
hospitals from 1994 to 2001 (Zambahari, 2004). 
 
Generally, the risk of CVD is correlated with elevated plasma levels of total 
cholesterol (TC) and low density lipoprotein cholesterol (LDLC) as well as low level 
of high density lipoprotein cholesterol (HDLC) (Hironori et al., 2005). 
Apolipoproteins are also used in risk assessment for cardiovascular disease. The 
plasma levels of apolipoprotein B 100 (Apo B100), apolipoprotein A-I (Apo A-I) and 
apolipoprotein E (Apo E) have been reported to be even more discriminatory in 
determining the risk of developing CHD than the cholesterol concentration (Kaptein 
et al., 1992). 
 
Despite the fact that cholesterol is essential in the body, its level should be 
maintained within normal range to preserve cell functions. The regulation of 
cholesterol synthesis and uptake from plasma in humans is dependent on coordinated 
changes in the level of mRNAs of key genes that are known to regulate cholesterol 
synthesis and cholesterol uptake (Horton et al., 2002). Genes including low-density 
lipoprotein receptor (LDLR), 3-hydroxy-3-methylglutaryl COA reductase (HMG-
COAR) and apolipoproteins such as Apo B100, Apo E and Apo A-1 are related with 
CVD and atherosclerosis. 
 
It has been established that increased LDLC is a risk factor for atherosclerosis and 
the underlying cause of CHD and stroke (Yilin et al., 2007). Low-density lipoprotein 
receptor (LDLR) is a key regulator of human plasma LDLC homeostasis (Brown and 
Goldstein, 1986). LDLR expressed on the surface of hepatocytes captures LDLC and 
internalizes it into the cells, leading to a decrease in circulation LDLC. Thus the 
expression level of LDLR directly influences the level of plasma LDLC (Brown and 
Goldstein, 1997). Up regulation of liver LDLR gene is effective in treating 
hypercholesterolemia (Kong et al., 2004) and is thus of primary importance in 
controlling the plasma cholesterol and further suggests a reduced risk of 
cardiovascular disease. 
 
Two-third of the body’s cholesterol is synthesized in the liver with 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-COA) reductase as the rate-limiting enzyme of 
the mevalonate pathway for cholesterol biosynthesis (Goldstein and Brown, 1990). 
Earlier studies showed that dietary cholesterol synthesis inhibits cholesterol 
synthesis, suggesting that cholesterol synthesis is a regulated process. Decrease 
cholesterol synthesis in response to cholesterol feeding seems to be the major 
compensatory mechanism to prevent an increase in whole body cholesterol levels 
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(Peter et al., 1996), whereas the increase of facial bile acid and neutral steroid 
excretion play secondary role in hypocholesterolemic and normal individuals (Cai 
and Carr, 1999). Up-regulation of LDLR and down-regulation of HMG-COAR are 
key mechanisms to control elevated plasma LDLC (Marc et al., 2004). The 
regulatory mechanisms that control expression of apolipoproteins genes are 
important since they represent the main structural components of the LDL and HDL 
particles, and their improper concentrations lead to cardiovascular disorders 
(Goldstein and Brown, 1997).  
 
The liver is the central organ in the cholesterol metabolism and plays an important 
role in whole body cholesterol homeostasis because it is an essential organ in the 
removal of excess cholesterol from the blood circulation for excretion into the bile 
(Spady et al., 1999). The liver regulates its intra hepatic cholesterol homeostasis, by 
maintaining an appropriate balance between the regulatory free cholesterol and the 
more inert cholesterol ester pool (Menno et al., 2005). The human hepatoma cell line 
HepG2 has been used as a suitable model for studying the cholesterol regulation and 
lipoprotein synthesis and metabolism (Kaptein et al., 1992). 
 
Among the most common pharmacological drugs currently used as lipid lowering 
agents in the clinical practices are statins. They act through inhibition of cholesterol 
synthesis and subsequent increase in hepatic LDLR expression (Kreisberg and 
Oberman, 2003). Statins effectively lower the plasma concentration of LDLC and 
reduce mortality and morbidity from CHD (Larosa et al., 1999). However, some 
patients are unable to tolerate statin treatments due to musculoskeletal symptoms and 
other side effects (Ballantyne et al., 2003; Rader, 2001). High rate of side effects 
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